International Medical Director (imd). Gu/hematology. Japac Region
Amgen UK
Singapore Affiliate, Singapore
On-site
Gu/hematology portfolio
Prostate cancer and all
Regional strategy and scientific engagement
Amgen UK is seeking an International Medical Director (IMD) for their GU/Hematology portfolio in the JAPAC region, based in Singapore. The role involves leading medical strategy, stakeholder engagement, and evidence generation for prostate cancer and acute lymphoblastic leukemia, requiring a strong background in oncology and medical affairs
Job Summary
The JAPAC International Medical Director (IMD) is a Singapore-based medical affairs role leading JAPAC regional strategy and scientific engagement for the GU and Hematology portfolio focused on prostate cancer and acute lymphoblastic leukemia (ALL).
The IMD partners with global medical leads and cross-functional teams to translate global strategy into JAPAC-relevant medical plans, supporting evidence generation, medical communications, and stakeholder engagement to inform registrational and lifecycle priorities.
Amgen is one of the world’s leading independent biotechnology companies, pioneering biotechnology breakthroughs to bring state-of-the-art medicines from laboratory to the patient.
Matching Summary
Match Score: 85
Amgen UK is seeking an International Medical Director (IMD) for their GU/Hematology portfolio in the JAPAC region, based in Singapore. The role involves leading medical strategy, stakeholder engagement, and evidence generation for prostate cancer and acute lymphoblastic leukemia, requiring a strong background in oncology and medical affairs.
Skills & Requirements
Must-have
GU/Hematology portfolio
prostate cancer and ALL
regional strategy and scientific engagement
evidence generation
medical communications
stakeholder engagement
Nice-to-have
scientific credibility
matrix leadership
analytical judgment
scientific rigor
Key Requirements
MD or DO degree
Minimum 5 years oncology Medical Affairs experience
Regional leadership experience
Experience in leading GU/Heme medical strategies across multiple JAPAC country affiliates